On May 11, 2017 Cellectar Biosciences, Inc. (Nasdaq: CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, reported financial results for first quarter of 2017 (Filing, Q1, Cellectar Biosciences, 2017, MAY 11, 2017, View Source [SID1234519059]). Management will host a teleconference and live webcast to review these results, including a review of corporate performance, at 4:30 PM ET today.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Summary of Q1 and Q2 2017 Accomplishments to Date:

· Positive safety, tolerability and activity data through Cohort 3 of Phase 1 study of CLR 131 in multiple myeloma

· Initiation of fourth cohort of Phase 1 study of CLR 131 in multiple myeloma

· Initiation of NCI-supported Phase 2 clinical trial of CLR 131 in multiple myeloma and other hematologic malignancies

· Consolidation of intellectual property portfolio for CLR 131 in multiple myeloma following license agreement with Wisconsin Alumni Research Foundation

· Publication in Nature Reviews Clinical Oncology and presentation at Academic Surgical Congress, both regarding PDC platform

· Additional intellectual property protection for CLR 131 in solid tumors in the US

· Grant of US patent for CLR 124 in PET imaging

· Additional US method of use patents for CLR 1501, CLR 1502 and an additional CLR 1401-boron-dipyrromethene analog for the detection of multiple cancer types

· Japanese composition of matter patent for CLR 1501 and CLR 1502

· Additional Japanese method of use patents granted for CLR 131 and CLR 125 in cancer stem cells

· Appointment of John Friend as chief medical officer

· Appointment of Doug Swirsky and Fred Driscoll to the Cellectar Board of Directors




"We continue to advance the clinical development of our lead product candidate, CLR 131, now in a fourth cohort of a Phase 1 trial for multiple myeloma, and an NCI-supported Phase 2 study in hematological malignancies. We have also successfully worked to enhance our intellectual property portfolio to protect the value in our pipeline," said Jim Caruso, president and CEO of Cellectar Biosciences. "The additions to our management team and board underscore our commitment to progressing Cellectar strategically as we continue our clinical and preclinical development programs."

Summary of Q1 2017 Financial Results:

Research and development expenses were $1.9 million, an increase of $0.8 million from the same period the prior year, largely a result of the increase in activities surrounding the initiation of the company’s Phase 2 clinical trial of CLR 131 in hematologic malignancies in addition to the ongoing Phase 1 trial in relapse/refractory multiple myeloma. General and administrative expenses totaled $1.0 million, consistent with Q1 2016.

The operating loss was $2.8 million, compared to $2.0 million in 2016. Net loss for the first quarter of 2017 was $2.9 million, or $0.24 per share, compared to net income of $0.8 million, or $0.96 per share, for the first quarter of 2016.

As of March 31, 2017, Cellectar reported $11.2 million in cash and cash equivalents on hand, compared to $11.4 million in cash and cash equivalents as of December 31, 2016.

Finally, the company received approximately $3 million from warrants exercised during the quarter, which extends Cellectar’s available cash and cash equivalents to fund planned operations into the second quarter of 2018. This is an improvement from the previous guidance of funding into the first quarter 2018. Additional capital will be required for operations beyond the second quarter of 2018.